Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.
Physics of Fluids Group, Technical Medical (TechMed) Centre, MESA+ Institute for Nanotechnology, University of Twente, The Netherlands.
Ultrasound Med Biol. 2020 Jun;46(6):1326-1343. doi: 10.1016/j.ultrasmedbio.2020.01.027. Epub 2020 Mar 11.
Microbubble ultrasound contrast agents have now been in use for several decades and their safety and efficacy in a wide range of diagnostic applications have been well established. Recent progress in imaging technology is facilitating exciting developments in techniques such as molecular, 3-D and super resolution imaging and new agents are now being developed to meet their specific requirements. In parallel, there have been significant advances in the therapeutic applications of microbubbles, with recent clinical trials demonstrating drug delivery across the blood-brain barrier and into solid tumours. New agents are similarly being tailored toward these applications, including nanoscale microbubble precursors offering superior circulation times and tissue penetration. The development of novel agents does, however, present several challenges, particularly regarding the regulatory framework. This article reviews the developments in agents for diagnostic, therapeutic and "theranostic" applications; novel manufacturing techniques; and the opportunities and challenges for their commercial and clinical translation.
微泡超声造影剂已经使用了几十年,其在广泛的诊断应用中的安全性和有效性已经得到了充分证实。成像技术的最新进展正在促进分子、3D 和超分辨率成像等技术的令人兴奋的发展,并且正在开发新的造影剂来满足它们的特定要求。与此同时,微泡在治疗应用方面也取得了重大进展,最近的临床试验证明了药物可以穿过血脑屏障并进入实体肿瘤。同样,新的造影剂也在针对这些应用进行定制,包括提供更优循环时间和组织穿透性的纳米级微泡前体。然而,新型造影剂的开发确实带来了一些挑战,特别是在监管框架方面。本文综述了诊断、治疗和“治疗诊断”应用的造影剂的发展、新型制造技术以及它们的商业化和临床转化的机遇和挑战。